Get started
Author

Savreet Bains Chawla

Observed names: Chawla, Savreet Bains, S Bains Chawla, S. Bains Chawla
OpenAlex ID: A5034210087
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
2025 · Alexey V. Danilov, Swetha Kambhampati Thiruvengadam, et al. · Blood Advances · 10
PDF
Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis
2025 · Dai Chihara, Shibing Yang, et al. · Blood Neoplasia · 6
Estimation of Relapsed/Refractory Follicular Lymphoma Patients on Therapy in the United States
2023 · Karissa Johnston, Mark Bennett, et al. · Blood · 3
Patterns of Care and Resource Use Among Elderly Relapsed/Refractory Follicular Lymphoma Patients: US Medicare Claims Analysis
2023 · Savreet Bains Chawla, Shibing Yang, et al. · Blood · 1
POSTER: IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND
2026 · Kim M Linton, Moshe Yair Levy, et al. · Clinical Lymphoma Myeloma & Leukemia
IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND
2026 · Kim M Linton, Moshe Yair Levy, et al. · Clinical Lymphoma Myeloma & Leukemia
Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US
2026 · Graff, Tara, Chawla, Savreet Bains, et al. · Figshare
Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US
2026 · Tara Graff, Savreet Bains Chawla, et al. · Future Oncology
PDF
Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL
2025 · Tara Graff, Savreet Bains Chawla, et al. · Blood
IBCL-770: Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second-Line or Later Follicular Lymphoma
2025 · Julie M. Vose, Paolo F. Caimi, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-770 Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second-Line or Later Follicular Lymphoma
2025 · Julie M. Vose, Paolo F. Caimi, et al. · Clinical Lymphoma Myeloma & Leukemia
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma
2025 · Zhijie Ding, Guihua Zhang, et al. · Future Oncology
PDF
241 | Matching‐adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second‐line + Follicular Lymphoma
2025 · J. M. Vose, P. F. Caimi, et al. · Hematological Oncology
PDF
248 | Matching‐adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Lisocabtagene Maraleucel in Second‐line Follicular Lymphoma
2025 · J. Villasboas, K. Yang, et al. · Hematological Oncology
PDF
Matching-Adjusted Indirect Treatment Comparison of Epcoritamab Versus Zanubrutinib Plus Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
2024 · Karen Cumings, Viktor Chirikov, et al. · Blood
PDF
Real‐world treatment patterns and clinical outcomes among follicular lymphoma patients in the SEER‐Medicare population
2023 · D. Chihara, S. Yang, et al. · Hematological Oncology
PDF
RWD17 Real-World Treatment Patterns and Overall Survival Among Follicular Lymphoma Patients: A SEER-Medicare Analysis
2023 · S. Yang, S Bains Chawla, et al. · Value in Health
PDF
Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States
2022 · Tycel Phillips, Junhua Yu, et al. · Blood
Works count: 19
Citation count: 20
H-index: 3
I10-index: 1
Year
Topic
Type